List of Excipients in Branded Drug ELURYNG

Generic Drugs Containing ELURYNG

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals LLC	etonogestrel and ethinyl estradiol	65162-469	ETHYLENE-VINYL ACETATE COPOLYMER
Amneal Pharmaceuticals LLC	etonogestrel and ethinyl estradiol	65162-469	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ELURYNG?

# Of NDCs	Excipient
1	ETHYLENE-VINYL ACETATE COPOLYMER
1	MAGNESIUM STEARATE

EluRyng Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

EluRyng is a generic contraceptive vaginal ring containing etonogestrel and ethinyl estradiol. Its commercial differentiation is limited because the product is an FDA-approved ANDA equivalent to NuvaRing and uses a simple, established excipient platform: an ethylene-vinyl acetate copolymer matrix with magnesium stearate. The strongest opportunities are in manufacturing efficiency, supply reliability, patient access, packaging, and next-generation vaginal-ring products rather than in substituting excipients within EluRyng itself.[1]

What is EluRyng and how does its formulation work?

EluRyng contains 11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol. The ring releases approximately 0.120 mg of etonogestrel and 0.015 mg of ethinyl estradiol per day over a three-week period.[1]

The active ingredients are dispersed in an ethylene-vinyl acetate copolymer matrix. Magnesium stearate is also listed as an inactive ingredient. The ring is designed for vaginal insertion, continuous hormone release, removal after three weeks, and a one-week ring-free interval.[1]

Product attribute	EluRyng specification
Active ingredients	Etonogestrel and ethinyl estradiol
Drug load	11.7 mg etonogestrel; 2.7 mg ethinyl estradiol
Daily release	Approximately 0.120 mg etonogestrel; 0.015 mg ethinyl estradiol
Dosage form	Vaginal ring
Primary polymer	Ethylene-vinyl acetate copolymer
Other listed excipient	Magnesium stearate
Administration cycle	Three weeks in place, one week removed
FDA pathway	Abbreviated New Drug Application
Reference product	NuvaRing
Manufacturer	Amneal Pharmaceuticals, Inc.

The formulation is a diffusion-controlled delivery system. Hormone release depends on the drug-polymer matrix, polymer composition, ring dimensions, drug loading, surface area, and manufacturing uniformity. Changes to any of these parameters can alter release rates, residual drug content, mechanical properties, or clinical performance.

What excipients are used in EluRyng?

The principal excipient is ethylene-vinyl acetate copolymer, commonly abbreviated EVA. EVA provides the flexible polymer matrix that holds the hormones and controls their migration into the vaginal environment.

Magnesium stearate is used in the product formulation, although the public label does not describe its precise processing function. In polymer-based drug delivery systems, magnesium stearate can support processing and reduce adhesion during manufacturing. Its role must be evaluated against possible effects on dispersion, surface properties, extractables, and drug release.

EluRyng’s excipient profile is commercially important for four reasons:

1. EVA is an established medical and pharmaceutical polymer.
2. The formulation avoids a complex aqueous, preservative-containing, or multilayer drug-delivery system.
3. The dosage form requires consistent polymer extrusion or molding.
4. The excipient platform is closely tied to the reference product’s performance and ANDA sameness requirements.

The formulation does not present the same excipient opportunity as an oral solid dose product, where manufacturers can often optimize disintegrants, binders, coatings, lubricants, or direct-compression performance. For EluRyng, the polymer matrix is part of the product’s delivery mechanism.

How strong is the EluRyng excipient strategy?

EluRyng has a technically conservative formulation strategy. That is appropriate for an ANDA product because the commercial objective is equivalence to NuvaRing rather than creation of a differentiated delivery system.

Strengths

The EVA matrix has a long development history in vaginal-ring contraception. It supports sustained release without pumps, reservoirs, batteries, or patient-controlled dosing. The ring is also compact, nonoral, and compatible with a three-week administration schedule.[1]

The limited excipient count reduces formulation complexity. A short inactive-ingredient list can simplify raw-material qualification, reduce analytical burden, and limit excipient-related regulatory questions.

Constraints

The same simplicity limits product differentiation. A competitor cannot freely replace EVA, change the polymer grade, modify the drug-loading ratio, or alter ring dimensions without assessing whether the resulting product remains pharmaceutically equivalent and therapeutically equivalent to the reference product.

Release performance is sensitive to polymer properties, including vinyl acetate content, molecular-weight distribution, crystallinity, plasticization, and processing temperature. Supplier changes can therefore create regulatory and quality risks even when the nominal excipient remains "ethylene-vinyl acetate copolymer."

Critical quality attributes include:

• Hormone content and content uniformity
• In vitro release rate
• Ring dimensions and weight
• Mechanical strength and flexibility
• Surface characteristics
• Residual drug content after use
• Extractables and leachables
• Microbiological quality
• Packaging integrity and stability

What commercial opportunities exist for EluRyng excipients?

The largest opportunities are operational and platform-based rather than based on a new inactive ingredient.

1. EVA supply-chain optimization

EVA resin qualification is a potential source of cost reduction and supply resilience. A manufacturer can qualify multiple suppliers or grades, subject to comparability and regulatory approval. The key commercial value is lower risk of interruption, not necessarily a lower nominal resin price.

Potential initiatives include:

• Dual sourcing of pharmaceutical-grade EVA
• Long-term resin contracts
• Supplier-specific process windows
• Improved resin drying and storage controls
• Reduced scrap during ring molding
• Automated dimensional inspection

Because the polymer is central to drug release, alternate-source qualification requires more than identity testing. It should include release-rate comparison, mechanical testing, extractables assessment, stability data, and process validation.

2. Manufacturing yield improvement

The product’s economics can improve through tighter control of extrusion, molding, cutting, joining, and surface finishing. Yield losses may arise from dimensional defects, incomplete joining, drug-content variability, or release-profile failures.

Automation can create value through:

• In-line diameter and thickness measurement
• Machine-vision inspection
• Gravimetric control of drug-polymer feedstock
• Automated ring joining
• Non-destructive defect detection
• Statistical process control for release testing

For a low-cost generic, manufacturing efficiency can have greater commercial impact than formulation redesign.

3. Packaging and distribution

EluRyng requires packaging that protects the polymer and hormones from heat, moisture, oxygen, and physical deformation. Packaging improvements may reduce stability failures, simplify distribution, or support mail-order contraception.

Opportunities include:

• Lower-cost high-barrier pouches
• Calendar-oriented packaging
• Unit-dose packaging for telehealth fulfillment
• Improved child-resistant features
• More efficient cold-chain avoidance, where supported by stability data
• Packaging that improves disposal instructions and patient handling

Packaging changes can create a practical lifecycle-management opportunity without changing the drug formulation. They still require stability and regulatory evaluation.

4. Patient-access products

A generic vaginal ring can compete on price, pharmacy availability, telehealth access, and continuity of supply. The main commercial barriers are patient familiarity, clinician prescribing habits, and insurance coverage.

A manufacturer or commercialization partner could differentiate through:

• Direct-to-consumer telehealth distribution
• Automatic refill programs
• Multi-month dispensing where permitted
• Patient education on insertion and removal
• Pharmacy benefit contracting
• Public-sector and reproductive-health distribution

These opportunities do not depend on a new excipient, but they increase the value of reliable and scalable ring manufacturing.

What formulations are protected by EluRyng-related patents?

EluRyng is an ANDA product referencing NuvaRing. The principal formulation concept, a vaginal ring using an EVA matrix to release etonogestrel and ethinyl estradiol, was developed and commercialized before EluRyng’s approval. The key historic intellectual-property issues concerned hormonal vaginal-ring structures, compositions, and controlled-release systems rather than a novel EluRyng-specific excipient innovation.[2]

Public FDA Orange Book records should be reviewed for current listed patents associated with the reference product and any relevant pediatric exclusivity or patent-term information.[3] The Orange Book is the operative source for listed patents and exclusivity status, while the FDA label identifies the approved product composition and administration instructions.

IP issue	EluRyng commercial relevance
EVA matrix formulation	Central to product performance and equivalence
Hormone release profile	May be protected through historic ring and controlled-release patents
Ring geometry	Can affect release and mechanical performance
Manufacturing process	May create trade-secret or process-patent barriers
Packaging	Potential lifecycle-management area
Method of contraception	Generally less differentiated for generic competition
Excipient substitution	Limited by equivalence and release-performance requirements

The commercial strength of EluRyng’s IP position is therefore not equivalent to the strength of an innovator’s patent estate. The product competes primarily through approval status, price, manufacturing capability, and market access.

When does EluRyng lose exclusivity?

EluRyng did not receive new chemical entity exclusivity because it is a generic product. FDA approved EluRyng in May 2019 through ANDA 209457.[4]

The product’s commercial protection is based on generic approval and market participation rather than an innovator exclusivity period. NuvaRing’s original commercial exclusivity and historic formulation patents expired or ceased to block generic entry before EluRyng reached the market. EluRyng therefore has no conventional branded-product exclusivity window comparable to a new molecular entity.

The relevant dates are:

Event	Date
NuvaRing FDA approval	2001
EluRyng FDA approval	May 2019
EluRyng regulatory pathway	ANDA 209457
Current exclusivity framework	Generic competition; no NCE exclusivity

FDA approval alone does not prevent later ANDA applicants from entering. Future competitors can seek approval by demonstrating bioequivalence and pharmaceutical equivalence, subject to applicable patent certifications and regulatory requirements.

Are there Paragraph IV challenges involving EluRyng?

EluRyng itself is the generic challenger rather than the reference product. Paragraph IV activity would generally arise when an ANDA applicant challenges patents listed for NuvaRing or another reference product.

Historic generic entry in this category involved patent certifications and litigation risk concerning the NuvaRing formulation and delivery system. After generic approval, the principal risk shifts from Paragraph IV litigation against the original reference product to ordinary generic competition, manufacturing disputes, product liability, supply agreements, and potential infringement claims involving later patents.

A commercial diligence review should distinguish among:

• Paragraph IV challenges to NuvaRing patents
• Patent litigation involving generic applicants
• Later patents covering manufacturing or packaging
• Trade-secret disputes involving polymer processing
• Contract disputes involving API, polymer, or finished-dose supply

The absence of a current prominent Orange Book barrier would support competitive entry, but each applicant must evaluate the live Orange Book record and applicable patent rights before launch.[3]

What FDA regulatory status does EluRyng have?

EluRyng is FDA-approved as a generic version of NuvaRing. It is a prescription combined hormonal contraceptive containing an estrogen and a progestin.[1,4]

The regulatory burden for a competing generic includes:

• Demonstration of pharmaceutical equivalence
• Bioequivalence or applicable comparative-performance evidence
• Comparable dosage form and route
• Comparable strength and release characteristics
• Manufacturing process validation
• Stability data
• Container-closure qualification
• Labeling consistent with the reference product, subject to permitted generic differences

For a vaginal ring, release testing is particularly important. Traditional oral-dose bioequivalence frameworks do not fully capture the technical significance of a polymer-controlled release system. Product developers must control both systemic exposure and in vitro release behavior.

What generic entry risks exist for EluRyng?

The principal generic-entry risks are moderate. The product has an established reference standard and a limited excipient system, but the dosage form is more difficult to manufacture than a conventional tablet or capsule.

Technical risks

• Inconsistent hormone dispersion in the EVA matrix
• Release-rate drift between lots
• Ring fracture or deformation
• Poor joining or surface defects
• Polymer supplier variability
• Extractables and leachables
• Stability loss under elevated temperature
• Incomplete removal or residual drug variability

Commercial risks

• Low reimbursement rates
• Limited patient awareness
• Substitution pressure from other hormonal contraceptives
• Competition from oral contraceptives, patches, injections, implants, and intrauterine systems
• Dependence on reproductive-health distribution channels
• Price erosion after multiple generic entries

Legal risks

• Patent claims covering modified ring geometries
• Process patents for hormone-polymer dispersion
• Manufacturing know-how disputes
• Packaging or device-related patent claims
• Product-specific patent listings not captured by a formulation-only review

Is there biosimilar risk for EluRyng?

No. EluRyng is a small-molecule combination drug delivered through a polymer vaginal ring. It is subject to generic-drug competition, not the biosimilar pathway under the Public Health Service Act.

Its competitive threats are other etonogestrel/ethinyl estradiol vaginal rings, branded or generic contraceptive alternatives, and non-ring contraceptive methods. The most relevant competitive products are NuvaRing and other vaginal-ring products with comparable hormone release objectives.

How does EluRyng compare with NuvaRing?

Category	EluRyng	NuvaRing
Regulatory status	Generic ANDA product	Reference branded product
Active ingredients	Etonogestrel and ethinyl estradiol	Etonogestrel and ethinyl estradiol
Delivery system	EVA vaginal ring	EVA vaginal ring
Administration	Three weeks in place, one week out	Three weeks in place, one week out
Primary commercial advantage	Lower-cost generic access	Brand recognition and historical market presence
Patent position	Generic product; limited standalone exclusivity	Historic innovator patent estate
Differentiation potential	Price, access, supply, packaging	Brand, physician familiarity, patient familiarity

EluRyng’s main strategic advantage is substitution economics. Its formulation is close to the reference product, so commercial success depends on manufacturing cost, availability, payer positioning, and distribution.

What licensing deals affect EluRyng?

EluRyng was developed and marketed by Amneal as a generic product. Publicly available FDA materials identify the product and applicant, but they do not establish a separate, publicly disclosed excipient-licensing transaction that creates a distinct EluRyng commercial right.[4]

The most relevant potential licensing structures in this market are:

• Contract manufacturing of EVA rings
• Licensed use of ring-molding technology
• API supply agreements for etonogestrel and ethinyl estradiol
• Co-development of next-generation vaginal rings
• Telehealth or pharmacy-distribution partnerships
• Regional commercialization rights

A licensee seeking differentiation would obtain more value from a new ring platform, longer-duration release profile, or improved patient-use system than from a minor excipient change to EluRyng.

What is the revenue exposure and commercial outlook?

Public company disclosures do not isolate EluRyng revenue in a way that supports a reliable product-level revenue estimate. The product’s revenue exposure should therefore be assessed through market share, prescription volume, net price, payer mix, and gross-to-net deductions rather than headline company revenue.

The market has several structural characteristics:

• Contraception has recurring demand.
• Generic substitution can expand access but compress net price.
• Vaginal rings occupy a smaller segment than oral contraceptives and long-acting reversible contraceptives.
• Supply reliability can determine pharmacy retention.
• A small number of manufacturers can create temporary supply advantages.
• A differentiated ring platform may command more value than a standard generic ring.

For investors and licensing teams, the strongest near-term opportunity is a low-cost, high-yield manufacturing platform with resilient polymer sourcing. The strongest longer-term opportunity is a differentiated vaginal-ring technology that extends duration, improves tolerability, expands contraceptive choice, or combines contraception with another vaginally delivered therapy.

What manufacturing and IP barriers affect EluRyng?

The manufacturing barrier is meaningful even though the excipient list is short. Controlled release from an EVA matrix requires reproducible formulation and processing. A company may be able to identify the ingredients from the public label but still lack the process knowledge needed to produce a ring with matching release, mechanical, and stability characteristics.

Important barriers include:

• Drug dispersion at production scale
• Thermal exposure during processing
• Ring dimensional control
• API-polymer compatibility
• Surface and joining consistency
• Release-test method development
• Extractables and leachables characterization
• Validation of packaging and storage conditions
• Regulatory comparability after supplier changes

Some of this protection may exist as trade secret rather than as an enforceable formulation patent. Process know-how can therefore remain commercially relevant after core product patents expire.

Key Takeaways

• EluRyng contains etonogestrel and ethinyl estradiol in an EVA polymer vaginal ring.
• The principal listed excipients are ethylene-vinyl acetate copolymer and magnesium stearate.[1]
• The EVA matrix controls hormone release and is the central technical element of the product.
• EluRyng is an ANDA-approved generic, not a product with new chemical entity exclusivity.[4]
• Commercial differentiation through excipient substitution is limited by pharmaceutical-equivalence and release-performance requirements.
• The best near-term opportunities are resin dual sourcing, manufacturing-yield improvement, automated inspection, packaging, and patient-access programs.
• The strongest longer-term opportunity is a new vaginal-ring platform with differentiated duration, dosing, or therapeutic use.
• EluRyng faces generic competition, not biosimilar competition.
• Product-level revenue is not publicly separable from broader company disclosures.
• Manufacturing know-how may remain a meaningful barrier even where core formulation patents no longer block entry.

FAQs

Can EluRyng use a different polymer from NuvaRing?

A different polymer could affect pharmaceutical equivalence, drug release, mechanical performance, and regulatory approval. A material substitution would require development and regulatory justification rather than a routine excipient change.

Is ethylene-vinyl acetate copolymer a patentable excipient opportunity?

EVA itself is an established polymer and is unlikely to provide meaningful standalone differentiation. Patent value is more likely to arise from a specific drug-polymer architecture, release profile, geometry, manufacturing method, or combination therapy.

Can EluRyng be reformulated for monthly or longer use?

A longer-use ring would likely be a new product-development program. It could require changes to drug loading, polymer structure, ring dimensions, release kinetics, toxicology, clinical exposure, and labeling.

What is the most valuable EluRyng lifecycle-management strategy?

The strongest strategies are improved supply reliability, lower manufacturing cost, packaging optimization, and distribution partnerships. A new excipient alone would offer limited value unless it produced a meaningful improvement in release, tolerability, stability, or use duration.

Does EluRyng have biologic-drug patent risk?

No. EluRyng is a small-molecule hormonal contraceptive. Its principal legal risks involve generic-drug patents, formulation and process rights, manufacturing know-how, and product-specific regulatory requirements.

References

1. U.S. Food and Drug Administration. (2019). EluRyng (etonogestrel and ethinyl estradiol vaginal ring) prescribing information.
2. U.S. Patent and Trademark Office. (n.d.). Patent records relating to etonogestrel and ethinyl estradiol vaginal-ring delivery systems.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2019). Drugs@FDA: EluRyng, ANDA 209457.